A study published in “Intestine” showed that long-term use of proton pump inhibitors will double the risk of gastric cancer . Proton pump inhibitors are a class of drugs used to treat gastric acid reflux. ,
Continuous use of this drug will eliminate Helicobacter pylori, which is closely related to the development of gastric cancer. In general, eliminating H. Helicobacter in the intestine can significantly reduce the risk of stomach cancer. But a considerable proportion of people still continue to develop gastric cancer. According to statistics, in recent years, gastric cancer has become the third leading cause of cancer death in the world.
Previously published research found a relationship between the use of proton pump inhibitors and increased risk of gastric cancer, but scientists have not been able to prove the potential role of H. pylori itself. In this study, scientists tried to bypass this problem. They compared the data of participants who used proton pump inhibitors with another type of drug. The first group of participants was the proton pump inhibitor group, and the second group of participants The data comes from the data of participants using histamine H2 receptor antagonists, which are a class of drugs used to inhibit acid production. The investigators followed them up for 7.5 years.
During this time, the researchers observed that although both groups of participants had chronic gastritis, the group using proton pump inhibitors doubled their risk of stomach cancer during the study period, while taking H2 receptors blocked Participants did not have high-risk changes. In addition, the researchers also found that more frequent use will bring greater risks, and daily use will increase the risk of gastric cancer by more than four times.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
